Tony Mok/prenetics.com
Jul 20, 2025, 13:06
Tony Mok Reviews Lung Cancer Clinical Trial Data for HER2-, HER3- and TROP-2-Targeted ADCs – ESMO
ESMO shared a post on LinkedIn:
“ESMO TAT Asia 25: In an Opinion piece in the ESMO Daily Reporter, Tony Mok reviews Lung Cancer Clinical Trial data for HER2-, HER3- and TROP-2-targeted Antibody Drug Conjugates (ADCs) as well as other novel targets.
While some of the early results are promising, questions remain around how to optimise ADCs to strike the right balance between efficacy and safety.
The future likely lies in further refining these agents, exploring new targets and incorporating more detailed biomarker analyses to guide treatment decisions.
Title: Target-led treatments for lung cancer – are they moving to the next level?
Author: Tony SK Mok
More posts featuring Tony Mok on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jul 20, 2025, 15:44
Jul 20, 2025, 15:33
Jul 20, 2025, 15:08
Jul 20, 2025, 14:31